Companies like Biogen and Royalty Pharma (Litifilimab), Biogen and UCB

渤健和Royalty Pharma（Litifilimab）、渤健和优时比

(Dapirolizumab pegol), Idorsia Pharmaceuticals and Viatris (Cenerimod), Novartis (Ianalumab, YTB3231), Kyowa Kirin (KK-4277), and others are advancing late, mid, and early-stage drugs, showing promise in the systemic lupus erythematosus treatment market.

Dapirolizumab pegol、Idorsia Pharmaceuticals 和 Viatris（Cenerimod）、Novartis（Ianalumab、YTB3231）、Kyowa Kirin（KK-4277）以及其他公司正在推进处于后期、中期和早期阶段的药物，在系统性红斑狼疮治疗市场中展现出前景。

LAS VEGAS

拉斯维加斯

,

，

July 9, 2026

2026年7月9日

/PRNewswire/ -- Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with disease severity and clinical manifestations varying considerably among patients. Despite significant advances in understanding its pathophysiology, SLE remains incurable, and current treatment strategies primarily focus on controlling disease activity, achieving remission or low disease activity, preventing irreversible organ damage, minimizing flares, and improving patients' long-term quality of life..

/美通社/ -- 系统性红斑狼疮（SLE）是一种慢性、复杂的自身免疫性疾病，可累及多个器官系统，其疾病严重程度和临床表现因患者而异。尽管在理解其病理生理学方面已取得显著进展，但系统性红斑狼疮仍无法治愈，目前的治疗策略主要集中在控制疾病活动度、实现缓解或低疾病活动度、预防不可逆的器官损伤、减少复发以及改善患者的长期生活质量。

The therapeutic landscape for SLE remains limited, with only two therapies currently approved by the US FDA specifically for the disease:

系统性红斑狼疮（SLE）的治疗选择仍然有限，目前美国食品药品监督管理局（FDA）仅批准了两种专门针对该疾病的疗法：

BENLYSTA

贝利尤单抗

(belimumab) from

（贝利尤单抗）来自

GlaxoSmithKline

葛兰素史克

and

和

SAPHNELO

SAPHNELO

(anifrolumab) from

（阿尼鲁单抗）来自

AstraZeneca

阿斯利康

. Conventional treatment continues to rely on nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial agents, glucocorticoids, immunosuppressants, and other supportive therapies.

常规治疗继续依赖非甾体抗炎药（NSAIDs）、抗疟药、糖皮质激素、免疫抑制剂以及其他支持性疗法。

While glucocorticoids remain a cornerstone of disease management, their well-documented long-term toxicities have intensified efforts to reduce steroid exposure through treat-to-target strategies. The persistent need for multiple lines of therapy and the limitations associated with existing treatments highlight the substantial unmet need for safer and more effective disease-modifying options..

尽管糖皮质激素仍是疾病管理的基石，但其长期毒性已有充分记录，这促使人们通过“达标治疗”策略加大努力，以减少类固醇暴露。对多线治疗的持续需求以及现有疗法的局限性，凸显出对更安全、更有效的疾病修饰治疗选项的巨大未满足需求。

Discover what is the future of the systemic lupus erythematosus (SLE) drugs market @

探索系统性红斑狼疮（SLE）药物市场的未来 @

https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market

https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market

The SLE pipeline is robust and increasingly diverse, with several late-stage and emerging therapies targeting novel immune pathways. Prominent investigational candidates include

系统性红斑狼疮（SLE）研发管线稳健且日益多元化，多种处于后期阶段及新兴的疗法正针对 novel 免疫通路。主要的在研候选药物包括

obinutuzumab

奥比努珠单抗

(Roche),

（罗氏）

ianalumab

伊那利珠单抗

(Novartis),

（诺华）

dapirolizumab pegol

达匹罗珠单抗聚乙二醇

(Biogen/UCB),

（渤健/优时比）

upadacitinib

乌帕替尼

(AbbVie),

（艾伯维）

deucravacitinib

德乌克拉维替尼

(Bristol Myers Squibb),

（百时美施贵宝）

litifilimab

利替非利单抗

(Biogen and Royalty Pharma), and other innovative agents that have the potential to improve disease control while reducing treatment-related toxicity.

（渤健和Royalty Pharma），以及其他有潜力在降低治疗相关毒性的同时改善疾病控制的创新药物。

Aparna Thakur, Project Manager of Forecasting at DelveInsight, said that Oral small molecules such as cenerimod (S1P1 modulator), deucravacitinib (TYK2 inhibitor), and upadacitinib (JAK1 inhibitor) target multiple immune pathways in SLE, reflecting a shift toward oral multi-pathway immune modulation in treatment..

DelveInsight 预测项目经理 Aparna Thakur 表示，诸如 cenerimod（S1P1 调节剂）、deucravacitinib（TYK2 抑制剂）和 upadacitinib（JAK1 抑制剂）等口服小分子药物针对系统性红斑狼疮（SLE）中的多种免疫通路，反映出治疗策略正转向口服多通路免疫调节。

In parallel, CAR T-cell therapies are emerging as a potentially transformative approach for patients with refractory SLE by enabling targeted B-cell depletion and immune system reprogramming that could deliver durable, treatment-free remission. Leading programs in this space include

与此同时，CAR T细胞疗法正成为一种可能具有变革性的方法，用于治疗难治性系统性红斑狼疮（SLE）患者，通过实现靶向B细胞清除和免疫系统重编程，有望带来持久且无需持续治疗的缓解。该领域的领先项目包括

rapcabtagene autoleucel (YTB-323), zolacabtagene autoleucel, resecabtagene autoleucel (CABA-201), and obecabtagene autoleucel (obe-cel, AUCATZYL)

拉普卡贝基因自体细胞（YTB-323）、佐拉卡贝基因自体细胞、雷塞卡贝基因自体细胞（CABA-201）以及奥贝卡贝基因自体细胞（obe-cel，AUCATZYL）

, signaling a potential shift from lifelong immunosuppression toward one-time disease-modifying interventions.

，标志着可能从终身免疫抑制转向一次性疾病修饰干预。

As per Thakur, CD19-directed CAR-T therapies, including rapcabtagene autoleucel, zolacabtagene autoleucel, and resecabtagene autoleucel, show strong potential in SLE by inducing deep B-cell depletion and durable remission, though safety risks such as CRS and ICANS require intensive monitoring.

据Thakur所述，包括rapcabtagene autoleucel、zolacabtagene autoleucel和resecabtagene autoleucel在内的CD19靶向CAR-T疗法，通过诱导深度B细胞清除和持久缓解，在系统性红斑狼疮（SLE）治疗中展现出强劲潜力，但细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）等安全风险需要密切监测。

Reflecting the growing innovation and expanding therapeutic opportunities in this space, DelveInsight estimates that the SLE market across the leading markets, including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately

反映了该领域日益增长的创新和不断扩大的治疗机会，DelveInsight估计，包括美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本在内的主要市场的系统性红斑狼疮（SLE）市场价值约为

USD 3 billion

30亿美元

in 2025 and is projected to grow at a

在2025年，并预计将以

CAGR of 10.4%

10.4% 的复合年增长率

through 2036.

至2036年。

Below, we highlight 6 emerging late-stage therapies poised to reshape the future of the systemic lupus erythematosus treatment market.

下文重点介绍6种有望重塑系统性红斑狼疮治疗市场未来的新兴后期疗法。

Biogen and Royalty Pharma's Litifilimab

渤健与Royalty Pharma的Litifilimab

CLEC4C protein inhibitors

CLEC4C蛋白抑制剂

Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody designed to target

Litifilimab（BIIB059）是一种人源化IgG1单克隆抗体，旨在靶向

BDCA2 (Blood Dendritic Cell Antigen 2)

BDCA2（血液树突状细胞抗原2）

and is being developed as a potential therapy for systemic lupus erythematosus (SLE). BDCA2 is a receptor primarily found on plasmacytoid dendritic cells (pDCs), a specialized immune cell population involved in the production of inflammatory mediators. By binding to BDCA2, litifilimab suppresses pDC activation, thereby reducing the release of type I interferons (IFN-I) along with other proinflammatory cytokines and chemokines implicated in SLE pathogenesis..

并正在被开发为系统性红斑狼疮（SLE）的潜在疗法。BDCA2是一种主要存在于浆细胞样树突状细胞（pDCs）上的受体，而pDCs是一类参与炎症介质产生的特化免疫细胞群。通过结合BDCA2，litifilimab抑制pDC的活化，从而减少I型干扰素（IFN-I）以及其他与SLE发病机制相关的促炎细胞因子和趋化因子的释放。

Biogen is currently evaluating litifilimab in two global Phase III clinical studies,

渤健目前正在两项全球III期临床研究中评估litifilimab，

TOPAZ-1 (NCT04895241) and TOPAZ-2 (NCT04961567)

TOPAZ-1（NCT04895241）和 TOPAZ-2（NCT04961567）

, for patients with SLE, with topline results anticipated by the end of 2026. In October 2025, the company announced that patient enrollment had been completed for both Phase III trials and that the expected data readout timeline had been accelerated to the second half of 2026. Earlier, in February 2025, Biogen entered into a funding agreement with .

，针对系统性红斑狼疮（SLE）患者，预计将于2026年底公布主要结果。2025年10月，公司宣布两项III期临床试验的患者入组工作均已完成，且预期数据读出时间表已提前至2026年下半年。此前，于2025年2月，Biogen与达成了资助协议。

Royalty Pharma

罗伊蒂制药

, under which it is eligible to receive up to

，根据该规定，其有资格获得最高达

USD 200 million

2亿美元

in 2025 and an additional

在2025年以及额外的

USD 50 million

5000万美元

in 2026 to help support the ongoing development of the litifilimab program.

在2026年，以支持litifilimab项目的持续开发。

Roche's Obinutuzumab (GAZYVA/GAZYVARO)

罗氏的奥比努珠单抗（GAZYVA/GAZYVARO）

TSLP inhibitor

TSLP抑制剂

Obinutuzumab is a glycoengineered monoclonal antibody designed to target the

奥比努珠单抗是一种糖工程化单克隆抗体，旨在靶向

CD20 protein

CD20蛋白

expressed on the surface of lymphoma and leukemia cells. As a type II anti-CD20 antibody, it exhibits greater antibody-dependent cellular cytotoxicity and stronger direct cell-killing activity compared with conventional CD20 antibodies. After binding to CD20, obinutuzumab promotes B-cell destruction by engaging immune effector cells, directly triggering intracellular death-signaling pathways, and activating the complement cascade.

表达于淋巴瘤和白血病细胞表面。作为一种II型抗CD20抗体，与传统的CD20抗体相比，它具有更强的抗体依赖性细胞介导的细胞毒性（ADCC）和更直接的细胞杀伤活性。奥比努珠单抗在与CD20结合后，通过招募免疫效应细胞、直接触发细胞内死亡信号通路以及激活补体级联反应，促进B细胞的破坏。

In Europe, the therapy is marketed under the name GAZYVARO..

在欧洲，该疗法以商品名GAZYVARO销售。

In February 2026, Roche submitted regulatory applications in the United States and Europe seeking approval of obinutuzumab for the treatment of Systemic Lupus Erythematosus. Subsequently, in April 2026, Roche announced that the FDA had accepted its

2026年2月，罗氏向美国和欧洲的监管机构提交了申请，寻求批准奥比努珠单抗用于治疗系统性红斑狼疮。随后，在2026年4月，罗氏宣布美国食品药品监督管理局（FDA）已受理其

supplemental Biologics License Application (sBLA)

补充生物制品许可申请（sBLA）

for obinutuzumab in SLE. The filing is based on positive results from the

用于系统性红斑狼疮（SLE）的奥比努珠单抗。该申报基于来自以下的阳性结果

Phase III ALLEGORY study

III期ALLEGORY研究

, which showed a statistically significant and clinically meaningful improvement in the primary endpoint. The FDA is expected to issue a decision on the application by

，该结果显示主要终点指标取得了具有统计学显著性和临床意义的改善。预计美国食品药品监督管理局（FDA）将在之前对该申请作出决定

December 2026

2026年12月

.

。

Discover more about which pipeline drugs could transform systemic lupus erythematosus treatment @

了解更多关于哪些在研药物可能变革系统性红斑狼疮的治疗 @

Systemic Lupus Erythematosus Market Size

系统性红斑狼疮市场规模

Novartis' Ianalumab

诺华公司的伊那利珠单抗

BAFF-R inhibitor, ADCC-mediated B-cell depletor

BAFF-R抑制剂，ADCC介导的B细胞清除剂

Ianalumab, a novel monoclonal antibody developed by Novartis, targets the

伊那鲁单抗是一种由诺华公司开发的新型单克隆抗体，靶向

B-cell Activating Factor Receptor (BAFF-R)

B细胞激活因子受体（BAFF-R）

. It is designed to inhibit BAFF-R signaling while simultaneously promoting B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC). The therapy is currently being evaluated in two Phase III clinical studies for systemic lupus erythematosus (SLE):

它旨在抑制BAFF-R信号传导，同时通过抗体依赖性细胞介导的细胞毒性（ADCC）促进B细胞清除。该疗法目前正在两项针对系统性红斑狼疮（SLE）的III期临床研究中进行评估：

NCT05639114 (SIRIUS-SLE 1) and NCT05624749 (SIRIUS-SLE 2)

NCT05639114（SIRIUS-SLE 1）和 NCT05624749（SIRIUS-SLE 2）

.

。

According to Novartis' 2026 interim financial report, topline results from the Phase III SIRIUS-SLE 1 and SIRIUS-SLE 2 trials are expected in

根据诺华2026年中期财务报告，SIRIUS-SLE 1和SIRIUS-SLE 2两项III期临床试验的顶线结果预计将于

2027

2027

. Pending positive outcomes, the company plans to submit Ianalumab for regulatory approval in SLE in

. 待取得积极结果后，公司计划提交伊那利珠单抗（Ianalumab）用于系统性红斑狼疮（SLE）的监管审批申请

2028

2028

.

。

Johnson & Johnson's Nipocalimab (IMAAVY)

强生公司的Nipocalimab（IMAAVY）

FcRn blockade

FcRn阻断

Nipocalimab is an investigational immunoselective therapy engineered to selectively bind with high affinity to the

尼泊卡利单抗是一种研究中的免疫选择性疗法，经工程化设计以高亲和力选择性结合

neonatal Fc receptor (FcRn)

新生儿Fc受体（FcRn）

, blocking its activity and lowering circulating pathogenic IgG antibodies while maintaining essential immune functions. The therapy is being evaluated across three major autoantibody-driven disease areas: rheumatologic disorders, rare autoantibody-mediated conditions, and maternal-fetal diseases, where inhibiting IgG interaction with FcRn in the placenta is expected to reduce the transfer of harmful maternal alloantibodies to the fetus.

，阻断其活性并降低循环中的致病性IgG抗体，同时维持必要的免疫功能。该疗法正在三大自身抗体驱动的疾病领域中进行评估：风湿性疾病、罕见的自身抗体介导疾病以及母胎疾病。在母胎疾病中，抑制IgG与胎盘FcRn的相互作用有望减少有害的母体同种抗体向胎儿的转移。

In March 2026, Johnson & Johnson announced that the U.S. Food and Drug Administration granted .

2026年3月，强生公司宣布美国食品药品监督管理局批准了。

Fast Track Designation (FTD)

快速通道认定（FTD）

to nipocalimab for the treatment of Systemic Lupus Erythematosus.

用于尼泊卡利单抗治疗系统性红斑狼疮。

Explore systemic lupus erythematosus competitors Johnson & Johnson marketed products @

探索系统性红斑狼疮竞争对手强生公司上市产品 @

Systemic Lupus Erythematosus Marketed Drugs

系统性红斑狼疮上市药物

Idorsia Pharmaceuticals and Viatris' Cenerimod

Idorsia制药公司和Viatris的Cenerimod

Sphingosine 1-phosphate receptor modulators

鞘氨醇-1-磷酸受体调节剂

Cenerimod is a highly selective

Cenerimod 是一种高度选择性的

Sphingosine-1-Phosphate Receptor 1 (S1P1) modulator

鞘氨醇-1-磷酸受体1（S1P1）调节剂

administered as a once-daily oral tablet. Although the exact cause of systemic lupus erythematosus remains unclear, dysregulated T and B lymphocytes are recognized as central drivers of disease pathogenesis. By selectively targeting the S1P1 receptor, cenerimod is designed to modulate lymphocyte trafficking and reduce immune-mediated inflammation.

每日一次口服给药。尽管系统性红斑狼疮的确切病因尚不明确，但T淋巴细胞和B淋巴细胞的失调被认为是疾病发病机制的核心驱动因素。通过选择性靶向S1P1受体，cenerimod旨在调节淋巴细胞的迁移并减少免疫介导的炎症。

The therapy is currently being evaluated in two .

该疗法目前正在两个中心进行评估。

Phase III clinical trials, OPUS-1 (NCT05648500) and OPUS-2 (NCT05672576)

III期临床试验，OPUS-1（NCT05648500）和OPUS-2（NCT05672576）

, for the treatment of SLE. The US FDA has also granted

，用于治疗系统性红斑狼疮（SLE）。美国食品药品监督管理局也已批准

Fast Track Designation (FTD)

快速通道资格认定（FTD）

to cenerimod, underscoring its potential to address an unmet medical need in SLE.

至cenerimod，强调其在解决系统性红斑狼疮（SLE）未满足医疗需求方面的潜力。

In February 2025, Idorsia Pharmaceuticals amended its collaboration agreement with

2025年2月，Idorsia Pharmaceuticals修订了其与

Viatris

晖致

for the development of cenerimod. Under the revised terms, Idorsia's contribution toward the drug's 2025 development costs was reduced by

用于cenerimod的开发。根据修订后的条款，Idorsia对该药物2025年开发成本的贡献减少了

USD 100 million

1亿美元

. In exchange, the company agreed to a

。作为交换，公司同意了

USD 250 million

2.5亿美元

reduction in future regulatory and commercial milestone payments while granting Viatris expanded territorial commercialization rights for cenerimod.

减少未来的监管和商业里程碑付款，同时授予Viatris更广泛的地区商业化权利以推广cenerimod。

AbbVie's RINVOQ (upadacitinib)

艾伯维的RINVOQ（乌帕替尼）

JAK 1 inhibitor

JAK1抑制剂

Upadacitinib (ABT-494) is a selective inhibitor of

乌帕替尼（ABT-494）是一种选择性抑制剂

Janus kinase 1 (JAK1)

Janus激酶1（JAK1）

that is approved for the treatment of several immune-mediated inflammatory diseases, including ankylosing spondylitis, atopic dermatitis, axial spondyloarthritis, Crohn's disease, giant cell arteritis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. In addition to its approved indications, the therapy is currently under clinical investigation for potential use in alopecia areata, hidradenitis suppurativa (HS), systemic lupus erythematosus (SLE), Takayasu arteritis, and vitiligo..

该药物已获批用于治疗多种免疫介导的炎症性疾病，包括强直性脊柱炎、特应性皮炎、中轴型脊柱关节炎、克罗恩病、巨细胞动脉炎、银屑病关节炎、类风湿性关节炎和溃疡性结肠炎。除了已批准的适应症外，该疗法目前正在进行临床研究，以评估其在斑秃、化脓性汗腺炎（HS）、系统性红斑狼疮（SLE）、大动脉炎和白癜风中的潜在应用。

AbbVie's RINVOQ (upadacitinib) continues to be an interesting lupus asset after its

艾伯维的RINVOQ（乌帕替尼）在其后继续成为一种有趣的狼疮资产

Phase 2 SLEek study

二期 SLEek 研究

showed meaningful activity in moderate to severe systemic lupus erythematosus, with the 30 mg monotherapy arm meeting the primary endpoint and achieving steroid-sparing benefit versus placebo. Updated data presented in 2023 also showed durability through 48 weeks, with fewer flares, longer time to first flare, and sustained improvements in disease-activity measures such as SRI-4, BICLA, and LLDAS, while no new safety signals were reported..

在中重度系统性红斑狼疮中显示出有意义的活性，其中30 mg单药治疗组达到主要终点，并与安慰剂相比实现减少激素用量的获益。2023年公布的更新数据还显示，疗效持续至48周，复发次数更少，首次复发时间延长，SRI-4、BICLA和LLDAS等疾病活动度指标持续改善，且未报告新的安全性信号。

The key development story is that AbbVie advanced RINVOQ into Phase 3 lupus testing after the positive Phase 2 readout, but it did not move forward with the ABBV-599 combination because elsubrutinib did not add enough efficacy to justify development.

关键进展是，在二期临床试验结果积极后，艾伯维将RINVOQ推进至系统性红斑狼疮的三期临床试验，但并未继续开发ABBV-599联合疗法，因为elsubrutinib未能提供足够的疗效以证明其开发价值。

Find out more about top SLE CAR-T pipeline assets @

了解更多关于顶级系统性红斑狼疮（SLE）CAR-T 管线资产的信息 @

Systemic Lupus Erythematosus Clinical Trials

系统性红斑狼疮临床试验

Source:

来源：

Systemic Lupus Erythematosus Market Report

系统性红斑狼疮市场报告

Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2036

系统性红斑狼疮市场洞察、流行病学及市场预测——2036年

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including

本报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键系统性红斑狼疮（SLE）企业，包括

GlaxoSmithKline, AstraZeneca, Genentech (Roche), AbbVie, Bristol Myers Squibb, Novartis, MorphoSys, UCB Pharma, Biogen, Juno Therapeutics, Johnson & Johnson Innovative Medicine, Idorsia Pharmaceuticals, Viatris, Merck

葛兰素史克、阿斯利康、基因泰克（罗氏）、艾伯维、百时美施贵宝、诺华、MorphoSys、优时比制药、渤健、Juno Therapeutics、强生创新制药、Idorsia Pharmaceuticals、晖致、默克

, and others.

，以及其他。

Related Reports

相关报告

Systemic Lupus Erythematosus Clinical Trial Analysis

系统性红斑狼疮临床试验分析

Complement 3 Glomerulopathy Pipeline Insight

补体3肾小球病研发管线洞察

–

–

2026

2026

report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including

报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键系统性红斑狼疮（SLE）企业的全面洞察，包括

Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Therapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, .

雅科生物、优时比（UCB）、索伦托治疗公司、三叶草生物制药、上海君实生物、Sareum、赛诺菲、罗氏、Rheos Medicine、Resolve Therapeutics、Provention Bio、辉瑞、诺华、Neovacs、默克、Medsenic、兰多斯生物制药、Kezar Life Sciences、康普生物制药、强生研发、杨森、和誉医药、ImmuPharma、天境生物、ILTOO、Idorsia Pharmaceuticals、Horizon Therapeutics、Genovax、Exinda Therapeutics、Equillium、礼来公司、卫材、第一三共株式会社、Corestem、Corbus Pharmaceuticals、Citryll BV、微芯生物、Carna Bioscience、百时美施贵宝、Brickell Biotech、Boston Pharmaceuticals、渤健、Athos Therapeutics、旭化成制药、Aria Pharmaceuticals、安腾基因治疗、安进、Alpine Immune Sciences、康方生物、艾伯维

and others.

以及其他。

JAK Inhibitors Market

JAK抑制剂市场

JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast

JAK抑制剂市场规模、目标人群、竞争格局与市场预测

–

–

2036

2036

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key JAK inhibitors companies, including

本报告提供对疾病的深入理解、历史及预测流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和关键JAK抑制剂公司，包括

Incyte Corporation, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Arcutis Biotherapeutics, Reistone Biopharma

Incyte公司、Aclaris Therapeutics公司、Sareum公司、武田制药、阿斯利康、Ajax Therapeutics公司、辉瑞公司、葛兰素史克、迪哲医药、Confluence Life Sciences公司、Celon Pharma公司、Arcutis Biotherapeutics公司、雷石生物制药

, and others.

，以及其他。

FcRn Inhibitors Market

FcRn抑制剂市场

FcRn Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast

FcRn抑制剂市场规模、目标人群、竞争格局及市场预测

–

–

2036

2036

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key FcRn inhibitors companies, including

报告提供对疾病的深入理解、历史和预测的流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和主要的FcRn抑制剂公司，包括

Immunovant, Viridian Therapeutics, argenx

Immunovant，Viridian Therapeutics，argenx

, and others.

以及其他。

TSLP Inhibitors Market

TSLP抑制剂市场

TSLP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast

TSLP抑制剂市场规模、目标人群、竞争格局与市场预测

–

–

2036

2036

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key TSLP inhibitors companies, including

报告提供对疾病的深入理解、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键TSLP抑制剂公司，包括

Sanofi, Uniquity Bio, Upstream Bio, Keymed Biosciences, Belenos Bioscience, Biosion, Pfizer

赛诺菲、Uniquity Bio、Upstream Bio、康诺思腾生物、贝洛诺斯生物科学、Biosion、辉瑞

, and others.

，以及其他。

About

关于

DelveInsight

DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来帮助制药公司提升业绩。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。

.

。

Contact Us

联系我们

Shruti Thakur

什鲁蒂·塔库尔

[email protected]

[email protected]

+14699457679

+14699457679

www.delveinsight.com

www.delveinsight.com

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight Business Research, LLP

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示